From the Department of Orthopaedic Surgery, University of California, Irvine, CA (Dr. Chin, Dr. Lim, and Dr. Scolaro), Orange, CA; the University of California, Irvine School of Medicine, Irvine, CA (Mr. Etiz); and the Department of Anesthesiology and Perioperative Care, Division of Pain Medicine, University of California (Dr. Nelson), Irvine, Orange, CA.
J Am Acad Orthop Surg Glob Res Rev. 2021 Apr 19;5(4):e21.00047. doi: 10.5435/JAAOSGlobal-D-21-00047.
Cannabinoids are an increasingly popular therapy among orthopaedic patients for musculoskeletal conditions. A paucity of evidence to support their use in orthopaedics exists, likely because of the incongruence of federal and state legalization and the stigma surrounding cannabis. The purpose of this study is to elucidate sentiments and knowledge base of the orthopaedic trauma community with regard to cannabinoid-containing compounds.
A 21-question online survey was distributed to the members of the Orthopaedic Trauma Association with a response window of 3 months.
We evaluated 251 responses. Most (88%) of the respondents did not believe that they were knowledgeable about the mechanism of action of cannabis/cannabidiol (CBD) but did feel that cannabis or CBD products play a role in managing postoperative pain (73%). Most respondents did not believe that they would be stigmatized if they suggested CBD (83%) or cannabis (67%) to patients. Despite this, fewer respondents have suggested CBD (38%) or cannabis (29%) to their patients.
Sentiment toward cannabinoids among orthopaedic traumatologists is remarkably favorable; however, in-depth understanding is admittedly poor and routine use is uncommon. More clinical research for cannabinoids is needed to help orthopaedic traumatologists provide guidance for patients seeking advice for this recently popular therapeutic.
大麻素类药物在骨科患者的肌肉骨骼疾病治疗中越来越受欢迎。由于联邦和州合法化之间的不一致以及大麻相关的污名化，支持其在骨科中应用的证据有限。本研究旨在阐明骨科创伤领域对含大麻素化合物的看法和知识基础。
向骨科创伤协会的成员分发了一份包含 21 个问题的在线调查，调查窗口为 3 个月。
我们评估了 251 份回复。大多数（88%）受访者表示他们对大麻/大麻二酚（CBD）的作用机制并不了解，但他们认为大麻或 CBD 产品在管理术后疼痛方面发挥着作用（73%）。大多数受访者认为，如果他们向患者建议 CBD（83%）或大麻（67%），他们不会受到歧视。尽管如此，仍有较少的受访者向他们的患者建议 CBD（38%）或大麻（29%）。
骨科创伤医生对大麻素的态度非常有利；然而，他们对其深入了解的程度较差，常规使用也不常见。需要更多的大麻素临床研究，以帮助骨科创伤医生为寻求这种最近流行的治疗方法的患者提供指导。
